• The challenges encountered in these markets are also numerous and include diverse languages and cultures, healthcare regulations, distribution challenges, preferential treatment for domestic companies and healthcare cost containment measures.
Key findings from this report- The vast opportunities for Pharmaceuticals in China appear more attainable than ever given the government's funding of major Healthcare Reforms to increase healthcare access, infrastructure and services between 2009 and 2011. These healthcare reforms aimed at expanding medical insurance and access while decreasing costs are expected to increase pharmaceutical volume at reduced prices.
- India, with its population of 1.1 billion, high levels of poverty and unmet medical needs and low healthcare expenditures continues to present challenges for the global industry. Opportunities include manufacturing skills including Biosimilar manufacturing. However, the lack of Intellectual Property recognition for several biologics, that prompted Novartis's shift of R+D investment from India to China, is a concern for the innovative industry.
- The large market shares of generics in the Emerging markets have resulted in numerous generic supply deals by companies including Pfizer, GSK, Sanofi Aventis, Novartis, Daiichi Sankyo and Abbott. Other companies that are seeking generic portfolios through alliances or acquisitions include Astra Zeneca, Lilly, J&J and Merck.
- Mylan and Teva appear to be potential alliance partners for companies seeking generics, based on their product portfolios and limited Emerging Market presence.
Key questions answered- What are the pharmaceutical market sizes, growth forecasts and unmet medical needs in the Emerging markets?
- Is there one definitive list of Emerging markets for Pharmaceuticals?
- What are the opportunities and challenges presented by the major Emerging Mark
Copyright©2010 PR Newswire.
All rights reserved